Personalizing Medicine through AI

Our Approach

Focused on Changing Breast Cancer Outcomes

PreciseDx® is dedicated to supporting more personalized and precise treatments for breast cancer.

 

On average, every two minutes a woman is diagnosed with breast cancer in the United States.

About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.

About PreciseDx

PreciseDx® is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.

Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists

Better Data. Better Outcomes.

PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.

  • Patients
  • Providers
  • Payers
  • BioPharma

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Patients

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

Providers

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

Payers

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

BioPharma

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Jack Zeineh, PreciseDx

Featured Resources & Media

Press Release
December 22, 2023
PreciseDx Collaborates with Baylor Scott & White Health to Validate PreciseBreast™ Assessment for Early-Stage Invasive Breast Cancer Detection
Media Coverage
November 14, 2023
Clinical Lab Products
Digital Morphology Solution Predicts Breast Cancer Recurrence
Publication
November 3, 2023
Clinical Breast Cancer
PreciseDx’s “Analytical Validation of a Digital Breast Cancer Test Predicting Recurrence in Early-Stage Breast Cancer” Featured in Clinical Breast Cancer

Interested in Learning More?

Contact Us